Publication:
FDA's Role in the Silicone Breast Implant Story

Thumbnail Image

Date

1997

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

FDA's Role in the Silicone Breast Implant Story (1997 Third Year Paper)

Research Data

Abstract

This paper will present the history of FDA's policy regarding silicone breast implants, as well as an analysis of the strengths and weaknesses of these actions. Although FDA Commissioner David Kessler's essential judgment that the implants had not been proven safe was sound, both in evaluating the nature and quality of the scientific evidence available, and in adhering to the Congressional guidelines for the type of proof necessary before a device can be approved for marketing, there were many flaws along the way.

Description

Other Available Sources

Keywords

Food and Drug Law, FDA,, silicone breast implants

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories